



## **XXVII CONGRESO NACIONAL SEIMC. Zaragoza, 30 mayo-1 de junio de 2024**

### **LO MEJOR DEL AÑO EN ENFERMEDADES INFECCIOSAS, INCLUIDO VIH**

José Antonio Iribarren Loyarte

Servicio de Enfermedades Infecciosas, Hospital Universitario Donostia, OSI-Donostialdea

Instituto de Investigación Sanitaria BioGipuzkoa (antes BioDonostia)

Euskal Herriko Unibertsitatea/Universidad del País Vasco, Departamento de Medicina

### **A) Artículos que nos hacen plantearnos si hemos de cambiar algunos aspectos de nuestra práctica clínica**

#### **1.- Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.**

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Moodliar R, Dodd M, Solodovnikova V, Liverko I, Rajaram S, Rassool M, McHugh T, Spigelman M, Moore DA, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL team. *Lancet Respir Med* 2024; 12: 117–28.

#### **2.- Adjunctive Dexamethasone for Tuberculous Meningitis in HIV-Positive Adults.**

Donovan J, Bang ND, Imran D, Nghia HDT, Burhan E, Huong DTT, Hiep NTT, Ngoc LHB, Thanh DV, Thanh NT, Wardhani ALS, Maharani K, Gasmara CP, Hanh NHH, Oanh PKN, Estiasari R, Thu DDA, Kusumaningrum A, Dung LT, Giang DC, Ha DTM, Lan NH, Chau NVV, Nguyet NTM, Geskus RB, Thuong NTT, Kestelyn E, Hamers RL, Phu NH, Thwaites GE; ACT HIV Investigators. *N Engl J Med* 2023; 389:1357-67.

#### **3.- Efficacy and safety of an early oral switch in low-risk *Staphylococcus aureus* bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial.**

Kaasch AJ, López-Cortés LE, Rodríguez-Baño J, Cisneros JM, Dolores Navarro M, Fätkenheuer G, Jung N, Rieg S, Lepeule R, Coutte L, Bernard L, Lemaigen A, Kösters K, MacKenzie CR, Soriano A, Hagel S, Fantin B, Lafaurie M, Talarmin JP, Dinh A, Guimard T, Boutoille D, Welte T, Reuter S, Kluytmans J, Martin ML, Forestier E, Stocker H, Vitrat V, Tattevin P, Rommerskirchen A, Noret M, Adams A, Kern WV, Hellmich M, Seifert H; SABATO study group. *Lancet Infect Dis* 2024; 24: 523–34.

#### **4.- Duration of antibiotic treatment for Gram-negative bacteremia – Systematic review and individual participant data (IPD) meta-analysis.**

Turjeman A, von Dach E, Molina J, Franceschini E, Koppel F, Yelin D, Dishon-Benattar Y, Mussini C, Rodríguez-Baño J, Cisneros JM, Huttner A, Paul M, Leibovici L, Yahav D. *eClinicalMedicine* 2023;55: 101750.



**5a.- Three Dengue Vaccines — What Now?**

Halstead SB. N Engl J Med 2024; 390:464-5.

**5b.- Evaluación de la vacunación frente al dengue en viajeros.**

GEPI/SEIMC.

Accesible

en

[https://seimc.org/contenidos/gruposdeestudio/gepi/Dcientificos/documentos/gepi-dc-2023-Vacunacion\\_dengue.pdf](https://seimc.org/contenidos/gruposdeestudio/gepi/Dcientificos/documentos/gepi-dc-2023-Vacunacion_dengue.pdf).

**6.- 2023 ESC Guidelines for the management of endocarditis.**

Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, Caselli S, Doenst T, Ederhy S, Erba PA, Foldager D, Fosbøl EL, Kovac J, Mestres CA, Miller OI, Miro JM, Pazdernik M, Pizzi MN, Quintana E, Rasmussen TB, Ristić AD, Rodés-Cabau J, Sionis A, Zühlke LJ, Borger MA; ESC Scientific Document Group. European Heart Journal (2023) 44, 3948–4042.

**7.- Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin AllergyThe PALACE Randomized Clinical Trial.**

Copaescu AM, Vogrin S, James F, Chua KYL, Rose MT, De Luca J, Waldron J, Awad A, Godsell J, Mitri E, Lambros B, Douglas A, Youcef Khoudja R, Isabwe GAC, Genest G, Fein M, Radojicic C, Collier A, Lugar P, Stone C, Ben-Shoshan M, Turner NA, Holmes NE, Phillips EJ, Trubiano JA. JAMA Intern Med. 2023; 183(9):944-952.

**8a.- Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.**

Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, Overton ET, Malvestutto CD, Bloomfield GS, Currier JS, Martinez E, Roa JC, Diggs MR, Fulda ES, Paradis K, Wiviott SD, Foldyna B, Looby SE, Desvigne-Nickens P, Alston-Smith B, Leon-Cruz J, McCallum S, Hoffmann U, Lu MT, Ribaldo HJ, Douglas PS; REPRIEVE Investigators. N Engl J Med 2023; 389:687-99.

**8b. Trial Update of Pitavastatin to Prevent Cardiovascular Events in HIV Infection.**

Grinspoon SK, Ribaldo HJ, Douglas PS. N Engl J Med 2024; 390:1626-8.

**9.- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bicitegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.**

Ramgopal MN, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S, Osiyemi O, Walmsley S, Sims J, Di Perri G, Sutton K, Sutherland-Phillips D, Berni A, Latham CL, Zhang F, D'Amico R, Pascual Bernáldez M, Van Solingen-Ristea R, Van Eygen V, Patel P, Chounta V, Spreen WR, Garges HP, Smith K, van Wyk J. Lancet HIV 2023; 10: e566–77.

**10.- Letemovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients. A Randomized Clinical Trial.**

Limaye AP, Budde K, Humar A, Vincenti F, Kuypers DRJ, Carroll RP, Stauffer N, Murata Y, Strizki JM, Teal VL, Gilbert CL, Haber BA. JAMA 2023; 330:33-42.



## **B) Artículos que nos alertan de potenciales cambios en el próximo futuro**

### **11a.- Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections.**

Hazra A, McNulty MC, Pyra M, Pagkas-Bather J, Gutierrez JI, Pickett J, Stewart J, Bolan RK, Molina JM, Celum C, Luetkemeyer AF, Klausner JD. Clin Infect Dis 2024; Feb 9:ciae062. doi: 10.1093/cid/ciae062. Online ahead of print.

**11b.- Documento de Posicionamiento sobre el uso profiláctico de doxiciclina para prevenir las ITS (DOXI-PEP) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) a través del Grupo de Estudio en Infecciones de Transmisión Sexual (GEITS), del Grupo de Estudio del Sida (GESIDA) y del Grupo de Estudio de los Mecanismos de Acción y de la Resistencia a los Antimicrobianos (GEMARA).** Marzo24. Accesible en:

<https://seimc.org/contenidos/documentoscientificos/recomendaciones/seimc-rc-2024-GEITS-GEMARA-GeSIDA-Posicionamiento-DoxiPEP.pdf>.

### **12.- Which form of tenofovir should be used worldwide: TDF or TAF?.**

Hill A. Clin Infect Dis. 2024 Apr 12:ciae190. doi: 10.1093/cid/ciae190. Online ahead of print.

### **13.- Crimean–Congo haemorrhagic fever virus in questing non-*Hyalomma* spp. ticks in Northwest Spain, 2021.**

Cuadrado-Matías R, Moraga-Fernández A, Peralbo-Moreno A, Negredo AI, Sánchez-Seco MP, Ruiz-Fons F. Zoonoses Public Health. 2024 Apr 8. doi: 10.1111/zph.13130. Online ahead of print.

### **14a.- Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.**

Hammond J, Fountaine RJ, Yunis C, Fleishaker D, Almas M, Bao W, Wisemandle W, Baniecki ML, Hendrick VM, Kalfov V, Simón-Campos JA, Pypstra R, Rusnak JM. N Engl J Med. 2024; 390:1186-1195.

### **14b.- Treating Acute Covid-19 — Final Chapters Still Unwritten.**

Gandhi RT, Hirsch M. N Engl J Med 2024; 390:1234-6.

### **15. Rapid diagnostic tests and antimicrobial stewardship programs for the management of bloodstream infection: what is their relative contribution to improving clinical outcomes? A systematic review and network meta-analysis.**

Peri AM, Chatfield MD, Ling W, Furuya-Kanamori L, Harris PNA, Paterson DL. Clin Infect Dis. 2024 Apr 27:ciae234. doi: 10.1093/cid/ciae234. Online ahead of print.



### **C) Algunos estudios equívocos**

**16.- Early Antiretroviral Therapy Not Associated With Higher Cryptococcal Meningitis Mortality in People With Human Immunodeficiency Virus in High-Income Countries: An International Collaborative Cohort Study.**

Ingle SM, Miro JM, May MT, Cain LE, Schwimmer C, Zangerle R, Sambatakou H, Cazanave C, Reiss P, Brandes V, Bucher HC, Sabin C, Vidal F, Obel N, Mocroft A, Wittkop L, d'Arminio Monforte A, Torti C, Mussini C, Furrer H, Konopnicki D, Teira R, Saag MS, Crane HM, Moore RD, Jacobson JM, Mathews WC, Geng E, Eron JJ, Althoff KN, Kroch A, Lang R, Gill MJ, Sterne JAC. Clin Infect Dis. 2023; 77:64-73.

**17.- Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.**

Griesel R, Zhao Y, Simmons B, Omar Z, Wiesner L, Keene CM, Hill AM, Meintjes G, Maartens G. Lancet HIV. 2023; 10:e433-e441.